Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

Authors: Camacho R, Clotet B, De Luca A, Geretti AM, Grossman Z, Kaiser R, Prosperi M, Schmit JC, Sönnerborg A, Torti C, Van Wijngaerden E, Vercauteren J, Zazzi M, Beheydt G, Imbrechts S, Libin P, Vandamme AM, Van Laethem K
Journal: PLoS One
Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0061436

Clinically evaluating genotypic interpretation systems is essential to provide optimal guidance in designing potent individualized HIV-regimens. This study aimed at investigating the ability of the latest Rega algorithm to predict virological response on a short and longer period.
Read More

Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

Authors: Abecasis A, Cabanas J, Camacho RJ, Gomes P, Libin P, Theys K, Van Laethem K
Publication Year: 2015
Journal: Journal of Clinical Virology
Link: http://www.ncbi.nlm.nih.gov/pubmed/26305833

BACKGROUND: Dolutegravir is approved for the treatment of HIV-1 patients exposed to other integrase inhibitors, but the decision to use dolutegravir in this setting should be informed by drug resistance testing. OBJECTIVES: This study determined the extent of disagreement in predicted residual dolutegravir activity after raltegravir use, and identified individual mutational patterns for which uncertainty […]
Read More

Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

About GHTM

Contacts

Funding